Paradromics Reports Four Years of Stable Neural Recording in BCI Implant

Paradromics has demonstrated four years of stable neural recording with its brain-computer interface technology, a durability benchmark that directly addresses one of the central obstacles in implantable neurotechnology: chronic signal degradation.

Four years of continuous, stable recording is the hard number at the core of the announcement. For clinical neurophysiology teams, chronic electrode stability is the variable that has limited earlier intracranial BCI efforts, where signal dropout and declining unit yield have historically forced device revisions or study endpoints to close early.

Paradromics develops a high-bandwidth implantable BCI intended for patients with severe motor impairment. The new long-term recording data indicates the company's electrode array can maintain usable neural signals over a multi-year horizon — the timescale any medically indicated BCI system must survive before it can be considered a durable therapeutic option.

Why chronic stability matters for implantable BCIs

Intracranial recording faces a well-known failure mode: over months to years, the electrode-tissue interface degrades, impedance drifts, and single-unit counts fall. A system that holds stable recordings across four years changes the engineering and regulatory calculus.

For reading rooms and monitoring units, the relevance is indirect but concrete. Scalp EEG remains the clinical workhorse, but investigational intracranial BCI platforms are increasingly referred into major neurosurgical centers, and electrophysiology teams will be asked to characterize baseline activity and follow implanted patients over time.

What the demonstration does — and does not — show

The data presented covers recording stability over a four-year period. As of this report, the announcement does not specify:

• Whether the recordings come from human participants or animal models
• The exact electrode count or channel density of the array used
• Specific signal-quality metrics, such as unit yield or impedance trends across the four-year window

The demonstration is investigational work. Paradromics' device is not FDA-cleared as a therapeutic product, and the long-term recording data should be read as engineering validation rather than evidence of clinical efficacy in a patient population.

Context for the BCI field

Paradromics is one of several companies pursuing high-channel-count implantable interfaces for patients with paralysis, alongside Neuralink, Blackrock Neurotech, and Synchron. Each platform faces the same chronic-durability question, and multi-year recording stability is emerging as a key competitive and regulatory differentiator.

The company's focus is a high-bandwidth cortical implant, aimed ultimately at restoring communication and movement for patients who have lost motor control — a population that includes people with amyotrophic lateral sclerosis, spinal cord injury, and stroke.

The road ahead

Demonstrating four years of stable neural recording positions Paradromics to advance toward longer-duration human implantation studies, where chronic signal durability will be tested against the demands of daily at-home use rather than laboratory conditions.